Entera Bio Stock

Entera Bio P/S

The (Price-Sales Ratio) is an important metric for stock valuation. It is calculated by dividing the current share price by the revenue per share. The P/S indicates how many years a company needs to generate the revenue per share as profit. A low P/S suggests that a stock may be undervalued, while a high P/S could indicate overvaluation. However, it is important to always consider the P/S in the context of the industry and the company. of Entera Bio (ENTX) as of Jul 19, 2026 is 301.49.

P/S

301.49

Last updated:

As of Jul 19, 2026, Entera Bio's P/S ratio stood at 301.49, a % change from the 0.00 P/S ratio recorded in the previous year.

The Entera Bio P/S history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/S
Date
P/S
Jan 1, 2019
108.34 base
Jan 1, 2020
53.77 base
Jan 1, 2021
129.05 base
Jan 1, 2022
161.78 base
Jan 1, 2023
0.00 base
Jan 1, 2024
440.99 base
Jan 1, 2025 (e)
0.00 base
Jan 1, 2026 (e)
47.39 base
YEARP/S
2026 est 47.39
2025 est -
2024 440.99
2023 -
2022 161.78
2021 129.05
2020 53.77
2019 108.34
2018 69.91
2017 -
2016 -
2015 -
Access this data via the Eulerpool API

Entera Bio Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Entera Bio's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Entera Bio's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Entera Bio's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Entera Bio grows earnings faster than its peers.

Entera Bio Stock analysis

What does Entera Bio do? Entera Bio Ltd is an emerging biotechnology company focused on developing oral medications to treat unmet medical needs. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Its history began with the discovery of the "EnteraGam" molecule in the intestinal cells of breastfed infants, which helps them fight infections. This led to the development of EnteraGam for the treatment of various autoimmune diseases. The company's business model is based on developing oral formulations for existing drugs and discovering and developing new molecules. Its focus areas are osteoporosis, hypoparathyroidism, chronic kidney disease, and autoimmune diseases. Entera Bio is divided into three business divisions: the Oral Protein Delivery Platform, the Oral Parathyroid Hormone (PTH) Platform, and the Collagen-based Platform for Wound Healing. Its products include EB611, a candidate for hypoparathyroidism treatment, EB613 for osteoporosis treatment, and EB612 for chronic kidney disease. These products have potential to improve the lives of millions of patients worldwide. Entera Bio is one of the most popular companies on Eulerpool.

P/S Details

Decoding Entera Bio's P/S Ratio

Entera Bio's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Entera Bio's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Entera Bio's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Entera Bio’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Entera Bio stock

(Price-Sales Ratio) is an important metric for stock valuation. It is calculated by dividing the current share price by the revenue per share. The P/S indicates how many years a company needs to generate the revenue per share as profit. A low P/S suggests that a stock may be undervalued, while a high P/S could indicate overvaluation. However, it is important to always consider the P/S in the context of the industry and the company. of Entera Bio is 301.49 in 2026.

The P/S ratio when valuing a stock.

The price-to-sales ratio (P/S ratio) is an important tool of technical analysis that assists investors in evaluating stocks. It refers to the earnings per share of a company and its price movements. This indicator can be used to determine a stock's fair value, relative to the company's earnings.

History of the Price-to-Sales Ratio

The price-to-sales ratio is a relatively new indicator. It was first used in the 1980s by John Price when he developed the Price-to-Sales Index (PSI). Price wanted to find a way to value stocks taking into account their earnings. He noticed that many stock prices were not in line with their earnings situation. The PSI has since become an important analytical tool and is often referred to as the P/S ratio.

Calculation of the price-to-sales ratio

The price-to-sales ratio is easy to calculate. It is determined by dividing the current stock price by the company's earnings per share. P/S ratio = Stock price / Earnings per share. For example, if a company's stock price is $10 and the earnings per share is $2, then the P/S ratio is 5.

Application of the Price-to-Sales Ratio

The Price-to-Sales ratio is a useful tool for determining a fairly valued stock price. A low P/S ratio may indicate that a stock price is undervalued, which could be a good entry opportunity. However, a high Price-to-Sales ratio may indicate that a stock price is overvalued and investors should exercise caution.

An example: A company has a stock price of 20 USD and an earnings per share of 2 USD. The P/E ratio is 10. This could indicate that the stock price is overvalued and investors should be cautious before buying.

Investors and the price-to-sales ratio

Investors use the price-to-sales ratio to determine whether a company's stock price is fairly valued or not. They can compare the P/S ratio to see how the stock price relates to the company's earnings. Investors can also observe the P/S ratio over a longer period of time to see if the stock price changes in relation to the company's earnings.

Advantages and Disadvantages of the Price-to-Sales Ratio

The greatest advantage of the price-to-sales ratio is that it is a simple and understandable tool to determine the fair value of a stock price. It can also help investors identify stocks that are undervalued. One disadvantage is that the P/S ratio does not provide information about the company's profits. Therefore, investors should also consider other financial ratios before investing.

In today's time, the price-to-sales ratio is an important tool for investors to evaluate stocks and identify potential investment opportunities. It can help find a fairly valued stock price and identify stocks that are undervalued. However, investors should also consider other financial indicators before making an investment decision.

Access this data via the Eulerpool API

Valuation — Entera Bio

All Key Metrics — Entera Bio